
Search
Filter Results
Displaying 121–130 of 624 for “retinal diseases”
-
Mar 6, 2025
With nearly two decades of leadership in vision and neuroscience research and a committed tenure with the Foundation, Dr. Laster will spearhead the Foundation’s scientific strategy in her new role.
-
Mar 13, 2025
Honoring the Legacy of Bob Reintsma: A Visionary in the Fight Against Blinding Diseases
Bob Reintsma was fiercely passionate about driving treatments and cures for blinding diseases for most of his life. The Foundation is extremely grateful for Bob’s dedication to our mission and legacy of generosity.
-
Feb 24, 2022
Second Sight Agrees to Merger to Maintain Retinal and Cortical Prostheses Programs
Company has been unable to meet revenue goals for the Argus II®
-
Dec 21, 2017
jCyte Reports Results for Phase 1/2a Clinical Trial for Retinal-Cell Treatment
Some participants reported increased light sensitivity, improved color vision, better mobility, and improved reading ability.
-
After a review by our Scientific Advisory Board (SAB), three key research gaps were identified: models to study retinal diseases, understanding how the immune system reacts, and finding biomarkers that can predict disease progression and help guide treatment decisions.
-
May 3, 2016
ARVO 2016: What Does It Take to Develop a Stem-Cell Therapy for the Retina?
There are innumerable considerations for researchers developing therapies.
-
Jan 10, 2013
Orphan Drugs Get Special Treatment
For developers of treatments for rare diseases — including inherited retinal conditions — “orphan” status provides valuable benefits, such as tax incentives, access to special research grants and assistance with clinical trial design.
-
The fiscal year 2025-2029 Science Strategic Plan is developed with a single, overarching goal: To drive research projects and activities to overcome barriers to translating preclinical research into clinical trials for individuals affected by inherited retinal diseases and dry AMD.
-
Apr 11, 2012
There's More Than One Way to Correct a Genetic Defect
A quick primer on genes and their critical role in building proteins.
-
Mar 20, 2014
UCI Stem-Cell Pioneer Poised to Launch Clinical Trial for RP Patients
Dr. Henry Klassen’s progenitor-based therapy has the potential to rescue a variety of retinal cells — including rods, cones, retinal pigment epithelium and ganglion cells — and, therefore, may save vision in people with a wide range of conditions.